HAVCR2 and cancer: Targeting other checkpoint molecules that have arisen interest in cancer research, as for example Lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin domain 3 (TIM-3) or T-cell immunoreceptor with immunoglobulin (Ig) and Immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), has not yet found its way into clinical uveal melanoma trials.